De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sunshine Biopharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Sunshine Biopharma's earnings have been declining at an average annual rate of -33.6%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 85.4% per year.
Belangrijke informatie
-33.6%
Groei van de winst
94.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 85.4% |
Rendement op eigen vermogen | -15.7% |
Nettomarge | -12.1% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues
Jan 29Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch
Sep 12Sunshine Biopharma acquires Nora Pharma for C$30M
Oct 20We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Aug 08Sunshine Biopharma reports 1H results
Aug 04Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Apr 17Opbrengsten en kosten
Hoe Sunshine Biopharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 30 | -4 | 12 | 2 |
31 Mar 24 | 27 | -4 | 11 | 2 |
31 Dec 23 | 24 | -5 | 11 | 2 |
30 Sep 23 | 20 | -27 | 14 | 1 |
30 Jun 23 | 15 | -28 | 13 | 1 |
31 Mar 23 | 9 | -27 | 12 | 1 |
31 Dec 22 | 4 | -27 | 9 | 1 |
30 Sep 22 | 0 | -3 | 3 | 1 |
30 Jun 22 | 0 | -5 | 2 | 1 |
31 Mar 22 | 0 | -7 | 2 | 1 |
31 Dec 21 | 0 | -12 | 2 | 1 |
30 Sep 21 | 0 | -14 | 2 | 1 |
30 Jun 21 | 0 | -11 | 2 | 0 |
31 Mar 21 | 0 | -9 | 2 | 0 |
31 Dec 20 | 0 | -3 | 1 | 0 |
30 Sep 20 | 0 | -2 | 1 | 0 |
30 Jun 20 | 0 | -2 | 1 | 0 |
31 Mar 20 | 0 | -1 | 1 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 0 | -1 | 0 | 0 |
30 Jun 19 | 0 | -2 | 1 | 0 |
31 Mar 19 | 0 | -2 | 1 | 0 |
31 Dec 18 | 0 | -2 | 1 | 0 |
30 Sep 18 | 0 | -2 | 1 | 0 |
30 Jun 18 | 0 | -1 | 1 | 0 |
31 Mar 18 | 0 | -1 | 1 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -2 | 1 | 0 |
30 Jun 17 | 0 | -3 | 1 | 0 |
31 Mar 17 | 0 | -3 | 1 | 0 |
31 Dec 16 | 0 | -3 | 1 | 0 |
30 Sep 16 | 0 | -3 | 1 | 0 |
30 Jun 16 | 0 | -2 | 1 | 0 |
31 Mar 16 | 0 | -2 | 0 | 0 |
31 Dec 15 | 0 | -2 | 0 | 0 |
30 Sep 15 | 0 | -1 | 1 | 0 |
30 Jun 15 | 0 | -1 | 1 | 0 |
31 Mar 15 | 0 | -2 | 1 | 0 |
31 Dec 14 | 0 | -2 | 1 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -2 | 1 | 0 |
31 Mar 14 | 0 | -2 | 1 | 0 |
Kwaliteitswinsten: SBFM is currently unprofitable.
Groeiende winstmarge: SBFM is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SBFM is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.
Versnelling van de groei: Unable to compare SBFM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SBFM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement op eigen vermogen
Hoge ROE: SBFM has a negative Return on Equity (-15.66%), as it is currently unprofitable.